Author:
Sadot Eran,Doussot Alexandre,O’Reilly Eileen M.,Lowery Maeve A.,Goodman Karyn A.,Do Richard Kinh Gian,Tang Laura H.,Gönen Mithat,D’Angelica Michael I.,DeMatteo Ronald P.,Kingham T. Peter,Jarnagin William R.,Allen Peter J.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
2. Marthey L, Sa-Cunha A, Blanc JF, et al. (2014) FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. doi: 10.1245/s10434-014-3898-9 .
3. Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–8.
4. O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142–8.
5. Bickenbach KA, Gonen M, Tang LH, et al. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol. 2012;19:1663–9.
Cited by
136 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献